• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ensysce Biosciences Inc (NQ: ENSC )

    0.3985 -0.0005 (-0.13%)
    Streaming Delayed Price Updated: 3:58 PM EDT, Jul 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 103,885
    Open 0.4000
    Bid (Size) 0.3900 (20)
    Ask (Size) 0.4135 (2)
    Prev. Close 0.3990
    Today's Range 0.3763 - 0.4050
    52wk Range 0.3711 - 2.200
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Ensysce Biosciences Provides Mid-Year 2024 Update
    Via ACCESSWIRE
    Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset
    Via ACCESSWIRE

    Performance

    YTD
    -64.10%
    -64.10%
    1 Month
    -24.10%
    -24.10%
    3 Month
    -28.66%
    -28.66%
    6 Month
    -70.04%
    -70.04%
    1 Year
    -81.38%
    -81.38%

    More News

    Read More
    Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting
    Via ACCESSWIRE
    Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate
    Via ACCESSWIRE
    ENSC Stock Earnings: Ensysce Biosciences Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program
    Via ACCESSWIRE
    Ensysce Biosciences to Participate in the EPHMRA 2024 Annual Meeting
    Via ACCESSWIRE
    Ensysce Biosciences Reports First Quarter 2024 Financial Results
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    Ensysce Biosciences Regains Compliance with Nasdaq
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
    Via ACCESSWIRE
    Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
    Via ACCESSWIRE
    Ensysce Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results
    Via ACCESSWIRE
    Ensysce Biosciences Announces Successful Meeting with FDA for PF614-MPAR, a Next Generation Opioid with Overdose Protection
    Via ACCESSWIRE
    Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
    Via ACCESSWIRE
    Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
    Via ACCESSWIRE
    FSR Stock: The $150 Million Reason Fisker Shares Are Moving Today
    Via InvestorPlace
    ENSC Stock Earnings: Ensysce Biosciences Misses EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Ensysce Biosciences Receives Positive Nasdaq Listing Determination
    Via ACCESSWIRE
    Ensysce Biosciences Announces Publication of Clinical Bioequivalence Manuscript
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.